Colorcon to buy BASF's Kollicoat coating system product

By Gareth Macdonald

- Last updated on GMT

Colorcon to buy BASF's Kollicoat coating system product

Related tags Marketing Active ingredient

Colorcon will buy BASF’s Kollicoat excipient coating system product line in a deal announced today.

The transaction – which is subject to approval by Brazilian competition authorities – will include BASF’s Kollicoat coating system product business, including its “current customer business, inventory and relevant know-how” according to Colorcon.

A Colorcon spokeswoman told us the firm will not be taking on any BASF staff or facilities involved in the manufacture of the Kollicoat coating product.

In addition to the coating system, BASF’s Kollicoat range comprises polymer excipients. The German chemical firm launched the newest Kollicoat product in the range last month​ at industry​ event in Glasgow, Scotland.

BASF spokesman Andres Christian Orthofer told us firm is only selling the coating systems part of its business to Colorcon, adding that “our Kollicoat product line has been and will remain a core part of our excipients business​.”

News of the coating system product sale comes a year after BASF sold the majority of its active pharmaceutical ingredients (API) business to Swiss fine chemicals firm Siegfried holding.

At the time​ BASF told us the divestiture will allow it to “focus its pharmaceutical business on its core expertise and unique strength in excipients and selected active pharmaceutical ingredients (APIs)."

The coating proaduct Colorcon will buy is not part of the industrial coatings business that BASF intends to sell to AkzoNobel for €475m ($529m).

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers